IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roader who wrote (1386)	12/3/1997 9:48:00 PM
From: Roger Cranwill	Read Replies (1) of 1762

It appears to me the announcement of the new arthritis drug being compared to CE9.1 implies the end of development of 9.1-anybody else read that into it? Roger IDEC (IDPH.O) antibody trial shows positive result SAN DIEGO, Dec 3 (Reuters) - IDEC Pharmaceuticals Corp said Wednesday said that a Phase I trial of a second-generation antibody it is developing for the treatment of rheumatoid arthritis showed several positive results. It said that trial on the product, Primatized anti-CD4 antibody IDEC-151/SB-217969, showed no depletion in CD4 cells, no infusion-related adverse events and longer coating action when administered at high doses compared to the first generation antibody, IDEC-CE9.1/SB-210396.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next